PT - JOURNAL ARTICLE AU - Marlon S. Zambrano-Mila AU - Monika Witzenberger AU - Anna Uzonyi AU - Ronit Nir AU - Shay Ben-Aroya AU - Erez Y. Levanon AU - Schraga Schwartz TI - Dissecting the basis for differential substrate specificity of ADAR1 and ADAR2 AID - 10.1101/2023.01.16.524339 DP - 2023 Jan 01 TA - bioRxiv PG - 2023.01.16.524339 4099 - http://biorxiv.org/content/early/2023/01/17/2023.01.16.524339.short 4100 - http://biorxiv.org/content/early/2023/01/17/2023.01.16.524339.full AB - Millions of adenosines are deaminated throughout the transcriptome by ADAR1 and ADAR2, modulating double-stranded RNA (dsRNA) immunogenicity and recoding mRNA. The high variability in the susceptibility of different adenosines to editing begs the question of what are the determinants of substrate specificity. Here, we systematically monitor how secondary structure modulates ADAR2 vs ADAR1 substrate selectivity, on the basis of systematic probing of thousands of synthetic sequences transfected into ADAR1-deleted cell lines exogenously expressing either ADAR2 or ADAR1. In both cases, structural disruptions gave rise to symmetric, strand-specific induced editing at a fixed offset, but of varying length: -26 nt for ADAR2, and -35 nt for ADAR1. We dissect the basis for the differences in offset between ADAR1 and ADAR2 via diverse mutants, domain-swaps, and ADAR evolutionary homologs, and reveal that it is encoded by the differential RNA binding domain architecture. We demonstrate that this offset-enhanced editing can allow an improved design of ADAR2-recruiting therapeutics, with proof-of-concept experiments suggestive of increased on-target and potentially decreased off-target editing. Our findings provide novel insight into the determinants guiding ADAR2 substrate selectivity and into the roles of the RNA binding domains of ADAR1 and ADAR2 in mediating differential targeting, and should facilitate the design of improved ADAR-recruiting therapeutics.Competing Interest StatementThe authors have declared no competing interest.